# IASO-782 in Autoimmune Hematological Diseases

> **NCT06534021** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai IASO Biotechnology Co., Ltd** · enrollment: 16 (estimated)

## Conditions studied

- Autoimmune Thrombocytopenia
- Warm Autoimmune Haemolytic Anaemia

## Interventions

- **DRUG:** IASO-782 injection
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06534021
- **Lead sponsor:** Shanghai IASO Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2025-11-01
- **Final completion:** 2025-11-01
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2024-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06534021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06534021, "IASO-782 in Autoimmune Hematological Diseases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06534021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*